Academic Users

For academic visitors to our website, we provide on this page selected CompBioMed links and services of particular interest to you. Please check out the links on the column to the right, and stay tuned for more content. If you are interested in working more closely with us or visiting one of our partners for a collaboration, check out our Visitor Programme page for more information

In silico heart assays on High Performance Computing

Before new medicines reach patients several tests are done to detect possible risks and side effects. This is the reason why drugs are tested on millions of animals worldwide each year. But this landscape is changing: research shows computer simulations of the heart have the potential to improve the drug development process and to reduce the need for animal testing.
Drug development requires a long and costly pipeline, where the drug is tested in a gradually more realistic setting (i.e. the experimental model), where animals are the last step before human volunteers. The challenge is to identify the correct threads for human health, and not to miss the potential risk or value of a drug for example due to the differences between animals and humans.

In silico human models

The revolutionary idea is to test a new drug in a “virtual human” organ, an experimental model entirely built on the circuits of a computer (i.e. in-silico). Recent research by the Computational Cardiovascular Science team at the University of Oxford demonstrates that computational models representing human heart cells show higher accuracy (89-96%) than animal models in predicting adverse drug effects such as dangerous arrhythmias – where the heart beat becomes irregular and can stop.

This research has recently been awarded with the International 3Rs Prize (from the National Centre for the Replacement Refinement and Reduction of Animals in Research) because of its potential to replace animal testing in labs. Instead of a one-model-fits-all method, the team uses an approach that simulates a wide range of responses under several conditions tested against experimental data. Everyone is different, and some drugs can have harmful side effects only for certain parts of the population, such as people with a specific genetic mutation or disease. This research also won the Technological Innovation Award at the Safety Pharmacology Society Meeting 2017.

This technology has been incorporated into a software, dubbed Virtual Assay, which is easy for non-experts to use in modelling and simulations. The software offers a simple user interface in which a control population of healthy cardiac cells with specific properties, based on human data, can be built. It can then be used to run in silico drug trials, before analysing the results. The whole process is very quick: it takes under five minutes using a modern laptop to test one drug in a population of 100 human cardiac cell models.

This research is part of a wider move towards the integration of computer models for drug safety testing which includes the Comprehensive in vitro Proarrhythmia Assay initiative, promoted by the US Food and Drug Administration and other organisations. The availability of high performance computing creates the possibility of running experiments with an unprecedented power, accounting for all the variability observed in the population and key related factors.

Pushing computer science boundaries

As part of the CompBioMed project we’re now working on 3D simulations of the heart to explore drug cardiac safety and efficacy on a larger scale. It also includes an exploration of diseased conditions, such as acute ischemia – where the blood flow in one of the arteries around the heart is obstructed. But while simulations of heart cells can run in a few minutes, 3D computer models of the whole heart still require a huge amount of computational power. The simulation of one heartbeat, for example, can take about three hours in a supercomputer with almost 1,000 processors.

The CCS team at the University of Oxford and the Barcelona Supercomputing Center have been awarded a PRACE Project Access on “In silico drug trials in the beating ischaemic human heart”, 2018-2020. This research is going to focus on developing a human electro-mechanical model of the heart using High Performance Computing (HPC) on the Marenostrum supercomputer. The project will conduct a proof of concept of a limited numbers of compounds and we will expand the investigations to consider a comprehensive list of medicines, building on the large datasets from our pharmaceutical industry collaborators. These models will be used to unravel key factors determining abnormalities caused by ischaemic disease and pharmacological therapy. Clinical imaging and electro-physiological dataset will be integrated to construct patient-specific anatomically –based electro-mechanical models of ischaemic human hearts, requiring tons of millions of nodes due to numerical constraints.

This research is part of a bigger movement towards the use of the virtual human and is being supported by the CompBioMed European project, an NC3Rs Infrastructure for Impact award, the TransQST European project, the PRACE project, an ARCHER project and the PIC project.


More examples of academic users:

  • Successful applicant for HPC-Europa3 programme - We are please to announce that Dr Grigor Arkelov, from the Academy of Sciences of the Republic of Armenia, Yerevan, has been awarded an HPC-Europa2 Transnational Access award, based at UCL, and will commence his 13 week visit within the next 6 months.
  • IEEE eScience 2018 paper accepted - Peter Coveney’s group at UCL have had a paper accepted for a talk IEEE eScience 2018. The paper is about “Concurrent and Adaptive Extreme Scale Binding Free Energy Calculations”. The IEEE eScience conference 2018 takes place in Amsterdam on 29 October – 1 November 2018.
  • A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules - A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules Denise S. M. Boulanger (1), Ruth C. Eccleston (2,3), Andrew Phillips (4), Peter V. Coveney (2,3,) Tim J. Elliott (1) and Neil Dalchau (4) 1 Centre for Cancer Immunology and Institute for Life Sciences, Faculty of Medicine, University of…
  • CompBioMed research wins the 11th IEEE International Scalable Computing Challenge - Our work executing and managing large and complex campaigns of ligand binding simulations (using our domain specific middleware, HTBAC) has won the 11th IEEE International Scalable Computing Challenge (SCALE 2018) at the IEEE/ACM International Symposium on Cluster, Cloud, and Grid Computing (CCGrid) 2018 held in Washington DC. The prize rewards real-world problem solving using computing…
  • PolNet software released under General License - A recent paper published through a collaboration of our coordinator, UCL, with our Associate Partner at the Centre for Medical Informatics at the University of Edinburgh, outlines the use and release of the PolNet software tool. PolNet is a software tool for the computer simulation of blood flow in realistic microvascular networks imaged with…